Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Alliance Global Partners
Deal Size : $5.0 million
Deal Type : Public Offering
Processa Closes $5M Public Offering Under Nasdaq At-The-Market Rules
Details : The net proceeds will used to fund the clinical development of PCS6422 (eniluracil), which is being evaluated for the treatment of breast neoplasms.
Product Name : PCS6422
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 30, 2025
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Alliance Global Partners
Deal Size : $5.0 million
Deal Type : Public Offering
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Alliance Global Partners
Deal Size : $5.0 million
Deal Type : Public Offering
Processa Prices $5M Public Offering Under Nasdaq At-The-Market Rules
Details : The net proceeds will used to fund the clinical development of PCS6422 (eniluracil), which is being evaluated for the treatment of breast neoplasms.
Product Name : PCS6422
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 27, 2025
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Alliance Global Partners
Deal Size : $5.0 million
Deal Type : Public Offering
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Pharmaceuticals Reports Positive Phase 1b Results with NGC-Cap in Cancer
Details : NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated for the treatment of gastrointestinal cancer.
Product Name : PCS6422
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 06, 2024
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
Details : NGC-Iri is a prodrug of SN-38, the active molecule in irinotecan and Onivyde. It is currently being evaluated for the treatment of cancers.
Product Name : NGC-Iri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2024
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Pharmaceuticals Announces FDA Clearance of NGC-Cap Phase 2 Trial in Breast Cancer
Details : PCS6422 is an analog of uracil that irreversibly inhibits dihydropyrimidine dehydrogenase (DPD) enzyme, being developed for the treatment of breast cancer.
Product Name : PCS6422
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 30, 2024
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of NGC-Cap
Details : PCS6422 is an analog of uracil that irreversibly inhibits dihydropyrimidine dehydrogenase (DPD) enzyme, being developed for the treatment of breast cancer.
Product Name : PCS6422
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2024
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Completes Phase 1b Safety study of NGC-Cap Advanced Cancer, Recommends Phase 2
Details : NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated in phase 1 clinical trials for gastrointestinal cancer.
Product Name : PCS6422
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2024
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : H.C. Wainwright & Co
Deal Size : $7.0 million
Deal Type : Public Offering
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
Details : The net proceeds will be used to advance the development of PCS6422 (eniluracil) administered in combination with capecitabine, for the treatment of advanced, refractory gastrointestinal tract tumors.
Product Name : PCS6422
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : Eniluracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : H.C. Wainwright & Co
Deal Size : $7.0 million
Deal Type : Public Offering
Lead Product(s) : Capecitabine,Eniluracil
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NGC-Cap combines the administration of PCS6422, the Company’s irreversible dihydropyrimidine dehydrogenase (DPD) enzyme inhibitor, with the administration of low doses of the commonly used chemotherapy capecitabine.
Product Name : NGC-Cap
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2023
Lead Product(s) : Capecitabine,Eniluracil
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PCS499
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Processa Pharmaceuticals To Move Forward With A PCS499 Phase 3 Trial After A Successful FDA Meeting
Details : With input from the FDA, Processa will be designing and conducting a Phase 3 trial to evaluate the ability of PCS499 to completely close ulcers in patients with NL.
Product Name : PCS499
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2020
Lead Product(s) : PCS499
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable